Viking Therapeutics (NASDAQ:VKTX) Shares Down 5%

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTXGet Free Report) were down 5% on Tuesday . The company traded as low as $73.40 and last traded at $75.52. Approximately 2,150,751 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 6,440,319 shares. The stock had previously closed at $79.50.

Analyst Ratings Changes

A number of equities research analysts have weighed in on VKTX shares. Jefferies Financial Group started coverage on Viking Therapeutics in a report on Thursday, March 7th. They issued a “buy” rating and a $110.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Viking Therapeutics in a report on Tuesday, March 26th. Truist Financial raised their price objective on Viking Therapeutics from $32.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, February 29th. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a report on Friday, February 23rd. Finally, BTIG Research lifted their target price on Viking Therapeutics from $100.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $112.25.

Read Our Latest Research Report on Viking Therapeutics

Viking Therapeutics Price Performance

The business has a 50-day moving average of $54.74 and a 200 day moving average of $28.58.

Viking Therapeutics (NASDAQ:VKTXGet Free Report) last issued its earnings results on Wednesday, February 7th. The biotechnology company reported ($0.25) EPS for the quarter, meeting analysts’ consensus estimates of ($0.25). During the same period in the prior year, the business earned ($0.26) earnings per share. On average, equities analysts anticipate that Viking Therapeutics, Inc. will post -1.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Viking Therapeutics news, Director Sarah Kathryn Rouan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $28.05, for a total transaction of $701,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Viking Therapeutics news, Director Sarah Kathryn Rouan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $28.05, for a total transaction of $701,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Brian Lian sold 269,079 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $26.87, for a total value of $7,230,152.73. Following the sale, the chief executive officer now directly owns 2,184,882 shares of the company’s stock, valued at $58,707,779.34. The disclosure for this sale can be found here. In the last ninety days, insiders sold 359,079 shares of company stock valued at $9,461,153. Corporate insiders own 4.40% of the company’s stock.

Institutional Trading of Viking Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Viking Therapeutics by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 5,381,904 shares of the biotechnology company’s stock worth $100,157,000 after buying an additional 97,552 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Viking Therapeutics by 88.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,119,885 shares of the biotechnology company’s stock worth $20,841,000 after buying an additional 525,296 shares during the last quarter. Virtu Financial LLC boosted its stake in shares of Viking Therapeutics by 15.1% in the 4th quarter. Virtu Financial LLC now owns 29,394 shares of the biotechnology company’s stock worth $547,000 after buying an additional 3,866 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Viking Therapeutics by 33.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 55,236 shares of the biotechnology company’s stock worth $1,028,000 after buying an additional 13,784 shares during the last quarter. Finally, Virtus ETF Advisers LLC boosted its stake in shares of Viking Therapeutics by 9.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,817 shares of the biotechnology company’s stock worth $90,000 after buying an additional 399 shares during the last quarter. 76.03% of the stock is owned by institutional investors.

Viking Therapeutics Company Profile

(Get Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Recommended Stories

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.